[ad_1]
11:12 PM
Thursday April 23, 2020
Washington – (dpa):
An antiviral drug has failed in its first randomized trials in people infected with the emerging coronavirus, in a setback amid hopes of finding a cure for the virus, according to a report released today, Thursday, as the number of deaths is rising across the board. the world.
The World Health Organization (WHO) inadvertently published a study of the drug Remedisfer, produced by the American company Gilead Sciences. The British newspaper “Financial Times” was the first to speak about the report.
The report indicated that the drug did not improve the condition of the patients.
The “Gilead” share price fell sharply in the context of the report, leading to a decline in the US market as the broader Standard & Poor’s index of the New York Stock Exchange lost its gains during the session. trading today.
The company did not immediately respond to a request for comment, but said in a statement to the “Financial Times” that the study was not completed, as it was “canceled early due to the small number of participants, and its results should not be considered scientific.” .
Gilead said “data trends” still indicate potential benefits for patients treated early.
The study was carried out in China, in 237 patients, of whom 158 underwent pharmacological treatment.
Other studies are underway in the United States of America, and these data are expected to begin publication in a few weeks.
The vaccines are also being tested, but they are still in their early stages, despite expert warnings that the development of any one may take until next year.
